Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Stoke Therapeutics Inc (NQ: STOK )

13.88 +0.61 (+4.60%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Stoke Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Credit Suisse Maintains Outperform Rating for Stoke Therapeutics: Here's What You Need To Know
Via Benzinga
6 Analysts Have This to Say About Stoke Therapeutics
Via Benzinga
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Expert Ratings for Stoke Therapeutics
Via Benzinga
Stoke Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Stoke Therapeutics, Inc.
Via Business Wire
Yum! Brands To Rally Around 20%? Here Are 10 Other Price Target Changes For Monday
Via Benzinga
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  On Friday, 72 companies hit new 52-week lows. 
Via Benzinga
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting
From Stoke Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's trading, 160 companies set new 52-week lows. 
Via Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  Monday saw 33 companies set new 52-week lows. 
Via Benzinga
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus... 
Via Benzinga
Why Opiant Pharmaceuticals Shares Are Trading Higher By 115%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Gainers Freight Technologies, Inc. (NASDAQ: FRGT) shares surged 137% to $0.4901 after analysts at Chardan Capital initiated coverage of the stock with a $2.25 price target. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers 
Via Benzinga
Hasbro, Ascendis Pharma, Coinbase Global And Some Other Big Stocks Moving Lower On Monday
U.S. stocks traded mixed, with the Nasdaq gaining more than 50 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Stoke Therapeutics Commences Initial-Stage Optic Nerve Disorder Study
Stoke Therapeutics (NASDAQ: STOK) has enrolled first patient in a prospective natural history study of people ages 8 to 60 who are living with autosomal dominant optic atrophy (ADOA). 
Via Benzinga
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)
From Stoke Therapeutics
Via Business Wire
7 Stocks Due for a Stunning Short Squeeze
If you can handle the heat, these ideas could potentially cook up some massive profits. 
Via InvestorPlace
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
From Stoke Therapeutics, Inc.
Via Business Wire
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.